JNJ News and Press, Johnson & Johnson From 06/20/24

TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction PR Newswire TREMFYA ® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa....

2024-06-19 00:00:00 ET Summary Breadth has been the topic of the week, with the market cap weighted S&P 500 pushing to new highs, leaving behind cumulative AD lines and equal-weight measures of the same index. The combined market cap of what are currently the 30 largest stocks...

2024-06-18 00:35:00 ET Summary After global M&A activity reached a decade low in 2023, dealmakers were banking on a rebound in 2024. So far, that hasn’t quite come to fruition when considering the total number of deal announcements which fell nearly 8% YoY in Q1​...

2024-06-17 09:00:40 ET Palm Beach, FL – June 17, 2024 – Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blo...

Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer PR Newswire Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administr...

2024-06-16 10:15:00 ET Summary Income investing is a delightful journey to financial independence. But this technique and the journey aren’t without pitfalls. We discuss seven fatal mistakes to avoid so you maintain your income sustainably recurring through market gyrat...

2024-06-16 08:12:27 ET Summary In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $...

2024-06-16 07:19:35 ET Summary Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and othe...

Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study PR Newswire Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to pat...

2024-06-14 17:53:40 ET Summary Vanguard Health Care ETF focuses on investing in successful healthcare companies with $20 billion in assets and a low expense ratio of 0.10%. Top holdings include Eli Lilly, UnitedHealth Group, and Johnson & Johnson, offering potential for growth...